Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Genscript Biotech stock price, quote, forecast and news

1548.HK
KYG3825B1059
A2ACSB

Price

1.66
Today +/-
+0.19
Today %
+13.32 %
P

Genscript Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Genscript Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Genscript Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Genscript Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Genscript Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Genscript Biotech Stock Price History

DateGenscript Biotech Price
9/27/20241.66 undefined
9/26/20241.45 undefined
9/25/20241.39 undefined
9/24/20241.40 undefined
9/23/20241.44 undefined
9/20/20241.59 undefined
9/19/20241.53 undefined
9/17/20241.56 undefined
9/16/20241.52 undefined
9/13/20241.49 undefined
9/12/20241.45 undefined
9/11/20241.41 undefined
9/10/20241.38 undefined
9/9/20241.37 undefined
9/5/20241.56 undefined
9/4/20241.53 undefined
9/3/20241.55 undefined
9/2/20241.49 undefined

Genscript Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Genscript Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Genscript Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Genscript Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Genscript Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Genscript Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Genscript Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Genscript Biotech’s growth potential.

Genscript Biotech Revenue, EBIT and net profit per share

DateGenscript Biotech RevenueGenscript Biotech EBITGenscript Biotech Net Income
2028e2.74 B undefined680.25 M undefined449.77 M undefined
2027e2.26 B undefined505.58 M undefined342.68 M undefined
2026e2.65 B undefined186.56 M undefined146.71 M undefined
2025e1.84 B undefined-62.77 M undefined12.55 M undefined
2024e1.22 B undefined-299.04 M undefined-144.12 M undefined
2023839.53 M undefined-387.42 M undefined-95.48 M undefined
2022625.7 M undefined-431.61 M undefined-226.85 M undefined
2021490.1 M undefined-522.24 M undefined-358.71 M undefined
2020390.85 M undefined-206.32 M undefined-204.95 M undefined
2019273.35 M undefined-123.76 M undefined-96.91 M undefined
2018231.02 M undefined8.67 M undefined21.22 M undefined
2017152.65 M undefined37.57 M undefined26.12 M undefined
2016114.74 M undefined26.37 M undefined26.17 M undefined
201586.71 M undefined19.62 M undefined17.5 M undefined
201469.99 M undefined7.95 M undefined6.18 M undefined
201360.1 M undefined7.7 M undefined6 M undefined
201253 M undefined11.1 M undefined9.2 M undefined

Genscript Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
0.050.060.070.090.110.150.230.270.390.490.630.841.221.842.652.262.74
-13.2115.0024.6432.5633.3351.9718.1842.8625.6427.5534.2445.6550.4144.34-14.6620.80
66.0463.3363.7766.2866.6768.4268.4065.9365.3857.5548.6448.75-----
353844577610415818025528230440900000
11771926378-123-206-522-431-387-299-62186505680
20.7511.6710.1422.0922.8124.343.46-45.05-52.82-106.53-68.96-46.13-24.47-3.377.0122.3124.86
96617262621-96-204-358-226-95-14412146342449
--33.33-183.3352.94--19.23-557.14112.5075.49-36.87-57.9651.58-108.331,116.67134.2531.29
1.21.21.21.231.711.731.841.861.92.042.12.1100000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Genscript Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Genscript Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
20122013201420152016201720182019202020212022
                     
0.020.030.030.10.140.130.560.430.771.41.46
89.212.116.7918.97253.5565.4169.67137.04135.1896.93
0.60.20.69.192.036.0617.1717.9828.6732.2675.35
1.21.41.82.034.246.8812.4319.8631.7544.3659.94
1.41.21.11.292.24.4719.8420.0224.5524.0769.4
0.030.040.040.130.160.40.680.550.991.641.76
39.538.837.737.8445.9282.97162.05274.21385.14505.42646.92
000001.7511.2814.7221.7125.3522.86
00000000022.4667.13
0.20.30.30.92.132.4719.6425.4826.0226.4223.81
00001.381.4715.2915.2514.1214.152.55
5.76.210.510.3212.6917.7129.265.77.2423.4685.29
45.445.348.549.0662.12106.37237.51335.37454.23617.27848.56
0.080.080.090.180.230.50.920.891.452.262.61
                     
0.40.40.41.61.691.731.841.881.952.12.11
00000.120.120.360.371.071.271.47
41.748.257.642.5869.8695.75124.9936.71-155.68-234.69-427.76
2.143.73.74-11.990.49-12.25-16.795.620.07-24.92
000000-0.010000
0.040.050.060.050.180.220.480.390.921.061.02
9.411.813.62.414.358.1511.1917.6323.3830.1855.76
4.46.27.67.5616.4614.3337.0289.15114.4156.11210.03
16.412817.5918.489.0994.8198.95142.91218.99235.41
00000010.516.4644.06033.23
00000002.323.178.0311.56
30.23029.227.5639.22111.58153.52224.51327.91413.31545.98
00000005.367.77148.42305.01
0.10000.450.344.025.587.037.738.01
1.11.41.41.932.35162.93266.15281.67289.1276.72324.71
1.21.41.41.932.8163.27270.16292.61303.9432.87637.74
0.030.030.030.030.040.270.420.520.630.851.18
0.080.080.090.080.220.490.90.911.551.912.21
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Genscript Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Genscript Biotech's financial health and stability.

Assets

Genscript Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Genscript Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Genscript Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Genscript Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
117722323822-113-281-496-431
3444561220324764
00000000000
-6-1-4-12-7-2726061-6125186
1133230110418560
00000000112
213276118-400
91212193321295-29-151-136-120
-9-8-7-7-8-29-71-111-127-137-203
-7-10-9-4-8-36-181-208-100-212-443
2-2-130-6-110-9627-75-239
00000000000
02-70-1010622-4825
00076112242-4610951423
0206582257-2624902419
007-11-114-5-80-29
00000-200000
1337832-12370-242376551-156
-0.43.54.6912.224.29-8.43223.91-141.67-278.84-274.19-323.86
00000000000

Genscript Biotech stock margins

The Genscript Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genscript Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genscript Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Genscript Biotech's sales revenue. A higher gross margin percentage indicates that the Genscript Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Genscript Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Genscript Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Genscript Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Genscript Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Genscript Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Genscript Biotech Margin History

Genscript Biotech Gross marginGenscript Biotech Profit marginGenscript Biotech EBIT marginGenscript Biotech Profit margin
2028e48.78 %24.87 %16.44 %
2027e48.78 %22.33 %15.14 %
2026e48.78 %7.03 %5.53 %
2025e48.78 %-3.42 %0.68 %
2024e48.78 %-24.47 %-11.79 %
202348.78 %-46.15 %-11.37 %
202248.6 %-68.98 %-36.26 %
202157.65 %-106.56 %-73.19 %
202065.47 %-52.79 %-52.44 %
201965.95 %-45.28 %-35.45 %
201868.63 %3.75 %9.18 %
201768.52 %24.61 %17.11 %
201666.44 %22.98 %22.81 %
201565.83 %22.63 %20.19 %
201463 %11.36 %8.82 %
201363.73 %12.81 %9.98 %
201266.79 %20.94 %17.36 %

Genscript Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Genscript Biotech earnings per share therefore indicates how much revenue Genscript Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genscript Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genscript Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genscript Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genscript Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Genscript Biotech Revenue, EBIT and net profit per share

DateGenscript Biotech Sales per ShareGenscript Biotech EBIT per shareGenscript Biotech Earnings per Share
2028e1.3 undefined0 undefined0.21 undefined
2027e1.08 undefined0 undefined0.16 undefined
2026e1.26 undefined0 undefined0.07 undefined
2025e0.88 undefined0 undefined0.01 undefined
2024e0.58 undefined0 undefined-0.07 undefined
20230.4 undefined-0.18 undefined-0.05 undefined
20220.3 undefined-0.21 undefined-0.11 undefined
20210.24 undefined-0.26 undefined-0.18 undefined
20200.21 undefined-0.11 undefined-0.11 undefined
20190.15 undefined-0.07 undefined-0.05 undefined
20180.13 undefined0 undefined0.01 undefined
20170.09 undefined0.02 undefined0.02 undefined
20160.07 undefined0.02 undefined0.02 undefined
20150.07 undefined0.02 undefined0.01 undefined
20140.06 undefined0.01 undefined0.01 undefined
20130.05 undefined0.01 undefined0.01 undefined
20120.04 undefined0.01 undefined0.01 undefined

Genscript Biotech business model

GenScript Biotech Corp. is a leading biotechnology company founded in Nanjing, China in 2002. Today, it is headquartered in New Jersey, USA and operates worldwide. Genscript Biotech is one of the most popular companies on Eulerpool.com.

Genscript Biotech SWOT Analysis

Strengths

1. Leading Biotech Company: GenScript Biotech Corp is a renowned biotech company known for its expertise and innovative solutions in the industry.

2. Established Brand: The company has a strong brand presence globally, with a reputation for quality products and services.

3. Diverse Product Portfolio: GenScript offers a wide range of biotech products and services, catering to the needs of customers from various sectors.

Weaknesses

1. Dependency on Research and Development: GenScript's success heavily relies on continuous research and development efforts, making it susceptible to any disruptions in these processes.

2. Vulnerability to Market Fluctuations: As a player in the biotech industry, GenScript is affected by market volatility, regulatory changes, and economic conditions, which may impact its financial stability.

3. Limited Geographic Presence: Although GenScript operates globally, its reach may be limited in certain countries, potentially hindering expansion opportunities.

Opportunities

1. Growing Demand for Biotech Solutions: The global biotech market is experiencing significant growth, providing opportunities for GenScript to capitalize on the increasing demand for its products and services.

2. Mergers and Acquisitions: GenScript can explore strategic partnerships, mergers, or acquisitions to expand its market presence, acquire new technologies, and gain a competitive edge.

3. Emerging Markets: Targeting emerging markets with high growth potential, such as Asia-Pacific and Latin America, can provide GenScript with new customers and revenue streams.

Threats

1. Intense Competition: The biotech industry is highly competitive, with numerous players vying for market share. Increased competition can pose challenges for GenScript in maintaining its market position.

2. Regulatory Risks: Adhering to complex and evolving regulations across different countries poses a potential risk for GenScript, as non-compliance could lead to penalties and reputational damage.

3. Technological Advancements: Rapid technological advancements in the biotech field can impact GenScript's offerings, making it crucial for the company to stay at the forefront of innovation.

Genscript Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Genscript Biotech historical P/E ratio, EBIT, and P/S ratio.

Genscript Biotech shares outstanding

The number of shares was Genscript Biotech in 2023 — This indicates how many shares 2.109 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genscript Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genscript Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genscript Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genscript Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Genscript Biotech dividend history and estimates

In 2023, Genscript Biotech paid a dividend amounting to 0 USD. Dividend means that Genscript Biotech distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Genscript Biotech provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Genscript Biotech’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Genscript Biotech's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Genscript Biotech Dividend History

DateGenscript Biotech Dividend
20170.01 undefined

Genscript Biotech dividend payout ratio

In 2023, Genscript Biotech had a payout ratio of 79.42%. The payout ratio indicates the percentage of the company's profits that Genscript Biotech distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Genscript Biotech represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Genscript Biotech could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Genscript Biotech's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Genscript Biotech Payout Ratio History

DateGenscript Biotech Payout ratio
2028e79.42 %
2027e79.42 %
2026e79.42 %
2025e79.42 %
2024e79.42 %
202379.42 %
202279.42 %
202179.42 %
202079.42 %
201979.42 %
201879.42 %
201779.42 %
201679.42 %
201579.42 %
201479.42 %
201379.42 %
201279.42 %
Unfortunately, there are currently no price targets and forecasts available for Genscript Biotech.

Genscript Biotech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.01 -0.03  (-223.53 %)2024 Q2
12/31/2023-0.05 -0.08  (-50.98 %)2023 Q4
6/30/20180.01 0.01  (-11.76 %)2018 Q2
12/31/20170.01 0.01  (-41.18 %)2017 Q4
1

Eulerpool ESG Scorecard© for the Genscript Biotech stock

Eulerpool World ESG Rating (EESG©)

78/ 100

🌱 Environment

71

👫 Social

99

🏛️ Governance

64

Environment

Scope 1 - Direct Emissions
12,090.92
Scope 2 - Indirect emissions from purchased energy
85,858.74
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
97,949.66
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees57.3
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Genscript Biotech list of shareholders

%
Name
Stocks
Change
Date
8.25568 % Hillhouse Capital Management Ltd.173,348,9658,578,00012/12/2023
38.09968 % Genscript Corporation799,999,12303/9/2024
1.50686 % The Vanguard Group, Inc.31,640,31903/31/2024
1.27418 % BlackRock Institutional Trust Company, N.A.26,754,600-68,0003/31/2024
1.14388 % Norges Bank Investment Management (NBIM)24,018,7239,181,37612/31/2023
1.12567 % GF Fund Management Co., Ltd.23,636,3217,894,00012/31/2023
1.08165 % HuaAn Fund Management Co., Ltd.22,712,0008,276,00012/31/2023
1.05193 % Bosera Asset Management Co., Ltd.22,088,0005,410,00012/31/2023
0.69322 % E Fund Management Co. Ltd.14,556,000670,00012/31/2023
0.50025 % Penghua Fund Management Co., Ltd.10,504,000216,00012/31/2023
1
2
3
4
5
...
10

Genscript Biotech Executives and Management Board

Mr. Jiange Meng55
Genscript Biotech Executive Chairman of the Board (since 2010)
Compensation 1.07 M
Ms. Ye Wang54
Genscript Biotech President, Co-Founder, Executive Director (since 2015)
Compensation 615,000
Dr. Li Zhu74
Genscript Biotech Executive Director, Chief Strategy Officer (since 2010)
Compensation 529,000
Dr. Fangliang Zhang58
Genscript Biotech Executive Director (since 2015)
Compensation 271,000
Mr. Jiuan Pan55
Genscript Biotech Non-Executive Independent Director
Compensation 180,000
1
2
3

Genscript Biotech Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
ABL Bio Stock
ABL Bio
SupplierCustomer0,860,630,850,18-0,38-0,37
AbClon Stock
AbClon
SupplierCustomer0,780,69-0,580,56-0,73
Legend Biotech ADR Stock
Legend Biotech ADR
SupplierCustomer-0,170,55-0,320,640,340,83
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer-0,76-0,71-0,78-0,77-0,490,58
1

Most common questions regarding Genscript Biotech

What values and corporate philosophy does Genscript Biotech represent?

Genscript Biotech Corp represents values of innovation, collaboration, and commitment to scientific advancement. With a strong corporate philosophy centered around providing quality products and services, Genscript strives to enhance the understanding and application of biotechnology worldwide. The company is dedicated to delivering cutting-edge research tools, custom solutions, and high-quality services to enable scientists and researchers in various fields. Genscript Biotech Corp aims to foster a culture of excellence, integrity, and customer-centricity, positioning itself as a global leader in the biotech industry.

In which countries and regions is Genscript Biotech primarily present?

Genscript Biotech Corp is primarily present in several countries and regions across the globe. The company has a strong foothold in China, where its headquarters are located. Additionally, Genscript Biotech Corp has a significant presence in the United States, with offices and operations spread across various states. The company has also established a strong international presence, with operations and collaborations in Europe, Asia, and other regions worldwide. With its global reach, Genscript Biotech Corp continues to expand its presence and deliver innovative solutions in the field of biotechnology.

What significant milestones has the company Genscript Biotech achieved?

Genscript Biotech Corp has achieved several significant milestones. As a leading biotechnology company, Genscript has made remarkable strides in the field. Notably, the company successfully completed the genome synthesis of the E. coli bacterium in 2010, which was a groundbreaking achievement. In 2015, Genscript became the first Chinese biotech firm to be listed on the Hong Kong Stock Exchange, marking a significant milestone for the company. Moreover, Genscript has continuously expanded its portfolio of services and products, catering to various research areas and providing innovative solutions to the scientific community. With such achievements, Genscript Biotech Corp stands as a prominent player in the biotech industry.

What is the history and background of the company Genscript Biotech?

Genscript Biotech Corp is a leading biotechnology company with a rich history and background. Established in 2002, the company specializes in providing high-quality services and products in the field of life sciences research. Genscript is dedicated to enabling advancements in scientific discoveries and breakthroughs through its expertise in gene synthesis, custom protein production, antibody development, and many other gene-related services. With its state-of-the-art facilities and a global customer base, Genscript has become a trusted partner for researchers and pharmaceutical companies worldwide. The company's commitment to innovation and excellence has helped propel it to the forefront of the biotech industry, making Genscript Biotech Corp a reliable choice for investors seeking opportunities in this dynamic sector.

Who are the main competitors of Genscript Biotech in the market?

The main competitors of Genscript Biotech Corp in the market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Sartorius AG.

In which industries is Genscript Biotech primarily active?

Genscript Biotech Corp is primarily active in the biotechnology industry.

What is the business model of Genscript Biotech?

The business model of Genscript Biotech Corp focuses on providing integrated solutions for life sciences research and drug discovery. The company offers a comprehensive range of products and services, including gene synthesis, protein expression, antibody development, and molecular diagnostics. Genscript Biotech Corp aims to accelerate biological research and development by providing high-quality and cost-effective solutions to scientists worldwide. Through its innovative technologies and expertise, the company has gained a strong reputation in the biotech industry. Genscript Biotech Corp continually strives to enhance its capabilities and expand its product portfolio to meet the evolving needs of the scientific community.

What is the P/E ratio of Genscript Biotech 2024?

The Genscript Biotech P/E ratio is -24.29.

What is the P/S ratio of Genscript Biotech 2024?

The Genscript Biotech P/S ratio is 2.87.

What is the AlleAktien quality score of Genscript Biotech?

The AlleAktien quality score for Genscript Biotech is 5/10.

What is the revenue of Genscript Biotech 2024?

The expected Genscript Biotech revenue is 1.22 B USD.

How high is the profit of Genscript Biotech 2024?

The expected Genscript Biotech profit is -144.12 M USD.

What is the business model of Genscript Biotech

GenScript Biotech Corp is a leading company in the biotech industry that specializes in the development and manufacture of high-quality biological products and services. The company offers a wide range of products and services, including DNA synthesis, protein production, antibody production, cell line development, and diagnostic tools. The company's divisions include proprietary products, manufacturing, and CRO (Contract Research Organization). Proprietary products contribute a large portion of the company's revenue and include various products such as CRISPR/Cas9 kits, DNA sequencing, protein analysis, and antibody services. GenScript Biotech's manufacturing business model is highly tailored to customer needs. It is based on critical procedures that incorporate proven expertise and patented technologies. The model includes a targeted approach to developing the necessary production processes, quality controls at every step of the manufacturing process, and support throughout the customer's entire lifecycle. An essential goal of the company is to support customers in every phase of the manufacturing process to ensure smooth and successful production. The Contract Research Organization (CRO) division of GenScript Biotech focuses on supporting customers in early stages of biological research or clinical trials. Through partnerships with the company, customers are supported through services such as protein engineering, cell line development, cell therapy, in vivo services, and pharmaceutical development. The company also offers a variety of diagnostic solutions and laboratory services. Examples include the development of cellular assays, reagent manufacturing, and DNA sequencing services. Overall, GenScript Biotech Corp is strongly focused on providing rapid and flexible service to its customers by offering a wide range of biopharmaceuticals, diagnostic tools, and laboratory services. The company has a global presence with offices in China, the USA, Europe, Japan, and Singapore. As a company that prioritizes innovation and quality, GenScript Biotech holds a strong position in the biotechnology market. With its various divisions and high-quality offering of products and services, the company provides its customers with a valuable partner to achieve their goals in biotechnology.

What is the Genscript Biotech dividend?

Genscript Biotech pays a dividend of 0 USD distributed over payouts per year.

How often does Genscript Biotech pay dividends?

The dividend cannot currently be calculated for Genscript Biotech or the company does not pay out a dividend.

What is the Genscript Biotech ISIN?

The ISIN of Genscript Biotech is KYG3825B1059.

What is the Genscript Biotech WKN?

The WKN of Genscript Biotech is A2ACSB.

What is the Genscript Biotech ticker?

The ticker of Genscript Biotech is 1548.HK.

How much dividend does Genscript Biotech pay?

Over the past 12 months, Genscript Biotech paid a dividend of 0.01 USD . This corresponds to a dividend yield of about 0.72 %. For the coming 12 months, Genscript Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Genscript Biotech?

The current dividend yield of Genscript Biotech is 0.72 %.

When does Genscript Biotech pay dividends?

Genscript Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genscript Biotech?

Genscript Biotech paid dividends every year for the past 4 years.

What is the dividend of Genscript Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genscript Biotech located?

Genscript Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genscript Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genscript Biotech from 6/21/2017 amounting to 0.012 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2017.

When did Genscript Biotech pay the last dividend?

The last dividend was paid out on 6/21/2017.

What was the dividend of Genscript Biotech in the year 2023?

In the year 2023, Genscript Biotech distributed 0 USD as dividends.

In which currency does Genscript Biotech pay out the dividend?

The dividends of Genscript Biotech are distributed in USD.

All fundamentals about Genscript Biotech

Our stock analysis for Genscript Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genscript Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.